Six-year follow-up of patients treated with oncoplastic reduction mammoplasty: A cohort study

• This study evaluates long-term recurrence rates in patients treated with oncoplastic reduction mammoplasty (ORM) for predominantly stage II-III cancers.
• Six-year local recurrence rate is 2%, distant recurrence rate is 6%, and cancer-specific survival is 96%.
• The study further supports that ORM is oncologically safe in the long-term.

BackgroundCurrent evidence for the oncological safety of oncoplastic breast conservation is poor as it is based mostly on short-term follow-up data. Hence, we report long-term recurrence rates in patients treated with oncoplastic reduction mammoplasty (ORM).MethodsA prospectively maintained database was searched to identify patients who underwent ORM between 2005 and 2010. A retrospective review of medical records was carried out, including patients with ductal carcinoma in situ and invasive breast cancer.ResultsFollow-up data from 65 consecutive patients with ORM were reviewed, of which 50 patients were eligible to measure long-term recurrence rates. The average weight of the resected tissue was 272 g altogether. The mean preoperative tumour size was 2.95 cm on imaging. 64% of patients had stage II – III cancers. Incomplete excision rate after ORM was 16.1%, completion mastectomy rate was 10.7%. During a median follow-up of 72 months, 2% local, 6% distant recurrence rates were detected. The breast cancer-specific survival rate was 96% per cent.ConclusionsBased on these long-term follow-up data, ORM is an oncologically safe treatment option.